Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's What Graham Capital Management Has Been Buying

By Selena Maranjian - Dec 26, 2012 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Keeping an eye on the big investors can introduce you to some compelling companies.

Every quarter, many money managers have to disclose what they've bought and sold, via 13F filings. Their latest moves can shine a bright light on smart stock picks.

Today, let's look at investing giant Graham Capital Management, founded in 1994 by Ken Tropin and in the multistrategy macro-oriented hedge fund business. The overall company manages investments for endowments, foundations, sovereign wealth funds, global pensions, investment advisors, and wealthy individuals, among others.

The company's reportable stock portfolio totaled $1.3 billion in value as of Sept. 30, 2012.

Interesting developments
So what does Graham Capital's latest quarterly 13F filing tell us? Here are a few interesting details.

The biggest new holdings are the PowerShares Dynamic Industrials ETF (NYSE: PRN) and calls on the Market Vectors Gold Miners ETF ( GDX 0.03% ). Other new holdings of interest include Dendreon (NASDAQ: DNDN) and Turquoise Hill Resources ( TRQ 3.24% ). Most investors in Dendreon, maker of expensive prostate-cancer drug Provenge, have lost a lot of money. But expectations may now be so low that the company could perform well from here -- though it's burning through a lot of cash, too. The company is raising some money by selling a U.S. facility to Novartis ( NVS -0.53% ), and some are watching to see whether Dendreon will get acquired in the near future. Meanwhile, my colleague Brenton Flynn found some interesting details about it in its financial statements.

Turquoise Hill is majority-owned by U.K.-based mining giant Rio Tinto ( RIO 0.98% ) and focuses primarily on mineral mining in central Asia and Australia. Its Oyu Tolgoi mine in Mongolia, which was 96% completed at the end of last quarter, is set to become one of the world's largest copper producers. The $7 billion company used to go by another name, Ivanhoe Mines, and its stock is down about 60% over the past year, making it more attractive to its fans. A potential problem has recently arisen, though, in the form of an alleged financial scandal in Mongolia -- interested investors should learn more before investing.

Among holdings in which Graham Capital increased its stake was Marvell Technology ( MRVL 4.21% ). The company's stock seems cheap these days, with the company whacked by weak PC sales. But its partnership with LED specialist Cree ( WOLF 4.04% ) to produce a dimmable LED bulb is promising, as is its potential to profit from the growth of cloud computing. Skeptics would like to see it profit more from the spread of smartphones. Its presence in Microsoft's ( MSFT 2.11% ) Surface tablets is promising, but it remains to be seen how successful the Surface will ultimately be. In the meantime, there's a new dividend, recently yielding nearly 3%, as well as stock repurchases.

Graham Capital reduced its stake in lots of companies, including France Telecom ( ORAN -0.74% ), which has long sported a hefty dividend yield, though that payout has been shrinking in recent years instead of growing. Part of the problem is the company's focus on Europe, which is a saturated and troubled market. It is expanding elsewhere, though, such as in sub-Saharan Africa, where its majority-owned Orange division's mobile service has been growing well. Bears don't like France Telecom's hefty debt load, but bulls like its dividend, its cash flow, and its growth potential, especially in emerging markets.

Finally, Graham Capital's biggest closed positions included puts on the iShares Silver Trust ETF ( SLV -0.98% ). Other closed positions of interest include Synta Pharmaceuticals (NASDAQ: SNTA). Synta is up nearly 90% over the past year, despite some seeing it with a "poor development track record." Bulls like recent insider and big-investor buying and are hopeful about phase 3 trial results for its cancer drug, ganetespib. There's a lot of potential here, but little is certain until some Synta drugs receive approval and sell well.

We should never blindly copy any investor's moves, no matter how talented the investor. But it can be useful to keep an eye on what smart folks are doing. 13F forms can be great places to find intriguing candidates for our portfolios.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Wolfspeed, Inc. Stock Quote
Wolfspeed, Inc.
$129.01 (4.04%) $5.01
Orange Stock Quote
$10.79 (-0.74%) $0.08
Turquoise Hill Resources Ltd. Stock Quote
Turquoise Hill Resources Ltd.
$14.97 (3.24%) $0.47
Microsoft Corporation Stock Quote
Microsoft Corporation
$336.63 (2.11%) $6.95
iShares Silver Trust Stock Quote
iShares Silver Trust
$21.16 (-0.98%) $0.21
Novartis AG Stock Quote
Novartis AG
$80.27 (-0.53%) $0.43
Marvell Technology Group Ltd. Stock Quote
Marvell Technology Group Ltd.
$75.02 (4.21%) $3.03
Rio Tinto plc Stock Quote
Rio Tinto plc
$62.94 (0.98%) $0.61
VanEck Vectors ETF Trust - VanEck Vectors Gold Miners ETF Stock Quote
VanEck Vectors ETF Trust - VanEck Vectors Gold Miners ETF
$32.13 (0.03%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.